[go: up one dir, main page]

PE20240913A1 - Anticuerpos anti-il-2r agonistas y metodos de uso - Google Patents

Anticuerpos anti-il-2r agonistas y metodos de uso

Info

Publication number
PE20240913A1
PE20240913A1 PE2023002728A PE2023002728A PE20240913A1 PE 20240913 A1 PE20240913 A1 PE 20240913A1 PE 2023002728 A PE2023002728 A PE 2023002728A PE 2023002728 A PE2023002728 A PE 2023002728A PE 20240913 A1 PE20240913 A1 PE 20240913A1
Authority
PE
Peru
Prior art keywords
seq
il2r
methods
antibodies
fewer substitutions
Prior art date
Application number
PE2023002728A
Other languages
English (en)
Inventor
Nathan Trinklein
Katherine Harris
Kyle Lorentsen
Chaudhry Harbani Kaur Malik
Kaitlyn Loughlin
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20240913A1 publication Critical patent/PE20240913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referido a anticuerpos que se une a IL2R, particularmente anti-IL2R agonistas que se une a IL2RB, que comprende una region variable de cadena pesada que comprende: (a) una secuencia de CDR1 que tiene dos o menos sustituciones en cualquiera de SEQ ID NO: 1-3; y/o (b) una secuencia de CDR2 que tiene dos o menos sustituciones en cualquiera de SEQ ID NO: 4-6; y/o (c) una secuencia de CDR3 que tiene dos o menos sustituciones en cualquiera de SEQ ID NO: 7-10. En donde el anticuerpo es multiespecifico. Tambien se refiere a una composicion farmaceutica que comprende dicho anticuerpo, metodos de elaboracion de estos anticuerpos y su uso en el tratamiento de enfermedades y trastornos que se median por la via de senalizacion de IL2/IL2R, como el cancer.
PE2023002728A 2021-04-02 2022-04-01 Anticuerpos anti-il-2r agonistas y metodos de uso PE20240913A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170383P 2021-04-02 2021-04-02
US202163239883P 2021-09-01 2021-09-01
PCT/US2022/023058 WO2022212848A1 (en) 2021-04-02 2022-04-01 Agonistic anti-il-2r antibodies and methods of use

Publications (1)

Publication Number Publication Date
PE20240913A1 true PE20240913A1 (es) 2024-04-30

Family

ID=81385128

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002728A PE20240913A1 (es) 2021-04-02 2022-04-01 Anticuerpos anti-il-2r agonistas y metodos de uso

Country Status (17)

Country Link
US (2) US11884735B2 (es)
EP (1) EP4314067A1 (es)
JP (1) JP2024512982A (es)
KR (1) KR20230165263A (es)
AU (1) AU2022252398A1 (es)
BR (1) BR112023020219A2 (es)
CA (1) CA3214587A1 (es)
CL (2) CL2023002895A1 (es)
CO (1) CO2023014054A2 (es)
CR (1) CR20230507A (es)
IL (1) IL305944A (es)
MX (1) MX2023011624A (es)
PE (1) PE20240913A1 (es)
PH (1) PH12023552763A1 (es)
TW (1) TW202304994A (es)
UY (1) UY39715A (es)
WO (1) WO2022212848A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
KR20250016462A (ko) 2016-12-21 2025-02-03 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
JOP20200157A1 (ar) 2017-12-22 2022-10-30 Teneobio Inc أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
PE20220575A1 (es) 2019-06-14 2022-04-20 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3
TW202304994A (zh) * 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217101A2 (en) 2024-04-09 2025-10-16 Amgen Inc. Agonistic anti-il-2rbg heavy‑chain antibodies
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
JP4282761B2 (ja) 1995-01-09 2009-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２ｒ結合ポリペプチド及びそれをコードするｄｎａ分子
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
AU2937597A (en) 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US6103879A (en) 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CN1703243B (zh) 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
PL2311874T3 (pl) 2004-07-22 2017-10-31 Univ Erasmus Med Ct Rotterdam Cząsteczki wiążące
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
TR201901445T4 (tr) 2015-08-06 2019-02-21 Agency Science Tech & Res Il2rbeta/yaygın gamma zinciri antikorları.
KR20250175345A (ko) 2016-06-21 2025-12-16 테네오바이오, 인코포레이티드 Cd3 결합 항체
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
EP3512549A4 (en) 2016-09-14 2020-06-17 Teneobio, Inc. Cd3 binding antibodies
TWI800552B (zh) 2017-11-10 2023-05-01 新加坡科技研究局 介白素2受體β(IL2Rβ)/共同γ鏈抗體
TW202031683A (zh) * 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
TW202039557A (zh) * 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
BR112021014074A2 (pt) 2019-02-01 2021-11-23 Regeneron Pharma Proteínas de ligação ao antígeno anti-receptor il2 gama
TW202304994A (zh) * 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法

Also Published As

Publication number Publication date
BR112023020219A2 (pt) 2024-02-06
CO2023014054A2 (es) 2023-11-10
US11884735B2 (en) 2024-01-30
JP2024512982A (ja) 2024-03-21
WO2022212848A1 (en) 2022-10-06
AU2022252398A9 (en) 2024-01-11
CL2025001688A1 (es) 2025-08-18
EP4314067A1 (en) 2024-02-07
CR20230507A (es) 2023-12-12
UY39715A (es) 2022-10-31
CA3214587A1 (en) 2022-10-06
IL305944A (en) 2023-11-01
AU2022252398A1 (en) 2023-09-21
MX2023011624A (es) 2023-10-11
TW202304994A (zh) 2023-02-01
KR20230165263A (ko) 2023-12-05
US20230242653A1 (en) 2023-08-03
US20240018250A1 (en) 2024-01-18
CL2023002895A1 (es) 2024-02-02
PH12023552763A1 (en) 2024-04-15

Similar Documents

Publication Publication Date Title
PE20240913A1 (es) Anticuerpos anti-il-2r agonistas y metodos de uso
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20241349A1 (es) Anticuerpos de union a cd3
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
PE20131209A1 (es) Anticuerpos anti-fap
EA202091747A1 (ru) Составы антитела b7-h4
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
PE20241584A1 (es) Proteinas que se unen a nkg2d, cd16 y baff-r
PE20211296A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
PE20121494A1 (es) Anticuerpos anti notch-1
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
PE20191743A1 (es) Anticuerpos biespecificos anti-pd-l1-anti-tim3
EA202192488A1 (ru) Антитела против tsg-6 и их применения
BR112022011323A2 (pt) Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos
AR122392A2 (es) Molécula aislada de enlace a b7-h3, polinucleótido aislado, composición farmacéutica para el tratamiento del cáncer y ensayo in vitro para el diagnóstico de cáncer
AR125288A1 (es) Anticuerpos anti-il-2r agonistas y métodos de uso
AR118621A1 (es) Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1
EA202190176A1 (ru) Антигенсвязывающий белок, связывающий steap1